Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05904691
PHASE1

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Sponsor: Ocugenix Corporation

View on ClinicalTrials.gov

Summary

Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD

Official title: Safety and Tolerability of Single Ascending Doses and Multiple Repeat Doses of OCU-10-C-110 for Injection in Study Participants With Neovascular Age-related Macular Degeneration (nAMD)

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

19

Start Date

2023-11-01

Completion Date

2026-11-30

Last Updated

2025-03-21

Healthy Volunteers

No

Interventions

DRUG

OCU-10-C-110 for Injection

OCU-10-C-110 for Injection in one of 3 doses

Locations (3)

Raj K. Maturi, M.D., P.C.

Carmel, Indiana, United States

Retina Research Institute of Texas

Abilene, Texas, United States

Strategic Clinical Research Group LLC

Willow Park, Texas, United States